CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome

George Z. Rassidakis, L. Jeffrey Medeiros, Simonetta Viviani, Valeria Bonfante, Gian Paolo Nadali, Theodoros P. Vassilakopoulos, Ofelia Mesina, Marco Herling, Maria K. Angelopoulou, Roberto Giardini, Marco Chilosi, Christos Kittas, Peter McLaughlin, M. Alma Rodriguez, Jorge Romaguera, Gianni Bonadonna, Alessandro M. Gianni, Giovanni Pizzolo, Gerassimos A. Pangalis, Fernando CabanillasAndreas H. Sarris

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Purpose: CD20 can be expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's disease (HD), but its clinical significance remains controversial. Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HD. Patients and Methods: Patients were eligible if they were previously untreated and human immunodeficiency virus-I negative, had biopsy-proven classical HD, and if pretreatment paraffin-embedded tumor tissue was available. CD20 expression was determined by immunohistochemistry without knowledge of clinical outcome. A tumor was considered positive if any HRS cells expressed CD20, but other cutoffs for number of CD20-positive HRS were also investigated. Results: We identified 598 patients whose median age was 30 years and of whom 55% were male. HRS cells expressed CD20 in 132 (22%) of 598 patients with classical HD. When any percentage of CD20 expression in HRS cells was used as a cutoff, the 5-year failure-free survival (FFS) for positive versus negative tumors was 86% versus 84%, respectively, for 302 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens (P = .7 by log-rank test), 74% versus 77%, respectively, for 181 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = .7 by log-rank test), 74% versus 84%, respectively, for 54 patients treated with MOPP (P = .4 by log-rank test), and 77% versus 88% for 53 patients treated only with radiotherapy (P = .5 by log-rank test). The 5-year FFS was not statistically different when cutoffs of 5% up to 50% for CD20-positive HRS cells were used. Conclusion: CD20 is expressed by HRS cells in 22% of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens.

Original languageEnglish
Pages (from-to)1278-1287
Number of pages10
JournalJournal of Clinical Oncology
Volume20
Issue number5
DOIs
Publication statusPublished - Mar 1 2002

Fingerprint

Reed-Sternberg Cells
Hodgkin Disease
Vinblastine
Survival
Radiotherapy
Neoplasms
Mitoxantrone
Dacarbazine
Bleomycin
Vincristine
Prednisone
Paraffin
Doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease : Associations with presenting features and clinical outcome. / Rassidakis, George Z.; Medeiros, L. Jeffrey; Viviani, Simonetta; Bonfante, Valeria; Nadali, Gian Paolo; Vassilakopoulos, Theodoros P.; Mesina, Ofelia; Herling, Marco; Angelopoulou, Maria K.; Giardini, Roberto; Chilosi, Marco; Kittas, Christos; McLaughlin, Peter; Rodriguez, M. Alma; Romaguera, Jorge; Bonadonna, Gianni; Gianni, Alessandro M.; Pizzolo, Giovanni; Pangalis, Gerassimos A.; Cabanillas, Fernando; Sarris, Andreas H.

In: Journal of Clinical Oncology, Vol. 20, No. 5, 01.03.2002, p. 1278-1287.

Research output: Contribution to journalArticle

Rassidakis, GZ, Medeiros, LJ, Viviani, S, Bonfante, V, Nadali, GP, Vassilakopoulos, TP, Mesina, O, Herling, M, Angelopoulou, MK, Giardini, R, Chilosi, M, Kittas, C, McLaughlin, P, Rodriguez, MA, Romaguera, J, Bonadonna, G, Gianni, AM, Pizzolo, G, Pangalis, GA, Cabanillas, F & Sarris, AH 2002, 'CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome', Journal of Clinical Oncology, vol. 20, no. 5, pp. 1278-1287. https://doi.org/10.1200/JCO.20.5.1278
Rassidakis, George Z. ; Medeiros, L. Jeffrey ; Viviani, Simonetta ; Bonfante, Valeria ; Nadali, Gian Paolo ; Vassilakopoulos, Theodoros P. ; Mesina, Ofelia ; Herling, Marco ; Angelopoulou, Maria K. ; Giardini, Roberto ; Chilosi, Marco ; Kittas, Christos ; McLaughlin, Peter ; Rodriguez, M. Alma ; Romaguera, Jorge ; Bonadonna, Gianni ; Gianni, Alessandro M. ; Pizzolo, Giovanni ; Pangalis, Gerassimos A. ; Cabanillas, Fernando ; Sarris, Andreas H. / CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease : Associations with presenting features and clinical outcome. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 5. pp. 1278-1287.
@article{13281f411aa64fd7b03ff62ffef4117d,
title = "CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome",
abstract = "Purpose: CD20 can be expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's disease (HD), but its clinical significance remains controversial. Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HD. Patients and Methods: Patients were eligible if they were previously untreated and human immunodeficiency virus-I negative, had biopsy-proven classical HD, and if pretreatment paraffin-embedded tumor tissue was available. CD20 expression was determined by immunohistochemistry without knowledge of clinical outcome. A tumor was considered positive if any HRS cells expressed CD20, but other cutoffs for number of CD20-positive HRS were also investigated. Results: We identified 598 patients whose median age was 30 years and of whom 55{\%} were male. HRS cells expressed CD20 in 132 (22{\%}) of 598 patients with classical HD. When any percentage of CD20 expression in HRS cells was used as a cutoff, the 5-year failure-free survival (FFS) for positive versus negative tumors was 86{\%} versus 84{\%}, respectively, for 302 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens (P = .7 by log-rank test), 74{\%} versus 77{\%}, respectively, for 181 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = .7 by log-rank test), 74{\%} versus 84{\%}, respectively, for 54 patients treated with MOPP (P = .4 by log-rank test), and 77{\%} versus 88{\%} for 53 patients treated only with radiotherapy (P = .5 by log-rank test). The 5-year FFS was not statistically different when cutoffs of 5{\%} up to 50{\%} for CD20-positive HRS cells were used. Conclusion: CD20 is expressed by HRS cells in 22{\%} of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens.",
author = "Rassidakis, {George Z.} and Medeiros, {L. Jeffrey} and Simonetta Viviani and Valeria Bonfante and Nadali, {Gian Paolo} and Vassilakopoulos, {Theodoros P.} and Ofelia Mesina and Marco Herling and Angelopoulou, {Maria K.} and Roberto Giardini and Marco Chilosi and Christos Kittas and Peter McLaughlin and Rodriguez, {M. Alma} and Jorge Romaguera and Gianni Bonadonna and Gianni, {Alessandro M.} and Giovanni Pizzolo and Pangalis, {Gerassimos A.} and Fernando Cabanillas and Sarris, {Andreas H.}",
year = "2002",
month = "3",
day = "1",
doi = "10.1200/JCO.20.5.1278",
language = "English",
volume = "20",
pages = "1278--1287",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease

T2 - Associations with presenting features and clinical outcome

AU - Rassidakis, George Z.

AU - Medeiros, L. Jeffrey

AU - Viviani, Simonetta

AU - Bonfante, Valeria

AU - Nadali, Gian Paolo

AU - Vassilakopoulos, Theodoros P.

AU - Mesina, Ofelia

AU - Herling, Marco

AU - Angelopoulou, Maria K.

AU - Giardini, Roberto

AU - Chilosi, Marco

AU - Kittas, Christos

AU - McLaughlin, Peter

AU - Rodriguez, M. Alma

AU - Romaguera, Jorge

AU - Bonadonna, Gianni

AU - Gianni, Alessandro M.

AU - Pizzolo, Giovanni

AU - Pangalis, Gerassimos A.

AU - Cabanillas, Fernando

AU - Sarris, Andreas H.

PY - 2002/3/1

Y1 - 2002/3/1

N2 - Purpose: CD20 can be expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's disease (HD), but its clinical significance remains controversial. Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HD. Patients and Methods: Patients were eligible if they were previously untreated and human immunodeficiency virus-I negative, had biopsy-proven classical HD, and if pretreatment paraffin-embedded tumor tissue was available. CD20 expression was determined by immunohistochemistry without knowledge of clinical outcome. A tumor was considered positive if any HRS cells expressed CD20, but other cutoffs for number of CD20-positive HRS were also investigated. Results: We identified 598 patients whose median age was 30 years and of whom 55% were male. HRS cells expressed CD20 in 132 (22%) of 598 patients with classical HD. When any percentage of CD20 expression in HRS cells was used as a cutoff, the 5-year failure-free survival (FFS) for positive versus negative tumors was 86% versus 84%, respectively, for 302 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens (P = .7 by log-rank test), 74% versus 77%, respectively, for 181 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = .7 by log-rank test), 74% versus 84%, respectively, for 54 patients treated with MOPP (P = .4 by log-rank test), and 77% versus 88% for 53 patients treated only with radiotherapy (P = .5 by log-rank test). The 5-year FFS was not statistically different when cutoffs of 5% up to 50% for CD20-positive HRS cells were used. Conclusion: CD20 is expressed by HRS cells in 22% of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens.

AB - Purpose: CD20 can be expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's disease (HD), but its clinical significance remains controversial. Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HD. Patients and Methods: Patients were eligible if they were previously untreated and human immunodeficiency virus-I negative, had biopsy-proven classical HD, and if pretreatment paraffin-embedded tumor tissue was available. CD20 expression was determined by immunohistochemistry without knowledge of clinical outcome. A tumor was considered positive if any HRS cells expressed CD20, but other cutoffs for number of CD20-positive HRS were also investigated. Results: We identified 598 patients whose median age was 30 years and of whom 55% were male. HRS cells expressed CD20 in 132 (22%) of 598 patients with classical HD. When any percentage of CD20 expression in HRS cells was used as a cutoff, the 5-year failure-free survival (FFS) for positive versus negative tumors was 86% versus 84%, respectively, for 302 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens (P = .7 by log-rank test), 74% versus 77%, respectively, for 181 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = .7 by log-rank test), 74% versus 84%, respectively, for 54 patients treated with MOPP (P = .4 by log-rank test), and 77% versus 88% for 53 patients treated only with radiotherapy (P = .5 by log-rank test). The 5-year FFS was not statistically different when cutoffs of 5% up to 50% for CD20-positive HRS cells were used. Conclusion: CD20 is expressed by HRS cells in 22% of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens.

UR - http://www.scopus.com/inward/record.url?scp=0036498728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036498728&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.5.1278

DO - 10.1200/JCO.20.5.1278

M3 - Article

C2 - 11870170

AN - SCOPUS:0036498728

VL - 20

SP - 1278

EP - 1287

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -